Skip to main content

Human response to COVID-vaccination in MS

This session is about the Human response to COVID-vaccination in MS. By Celia Oreja-Guevara.

9th December 2021, Pre-MENACTRIMS symposium, as a warm-up for the Sixth MENACTRIMS Congress, ParadigMS Foundation organised this enriching Pre-MENACTRIMS Symposium. Here you can review the full keynote on Human response to COVID-vaccination in MS.

ABSTRACT

Most multiple sclerosis (MS) patients infected with COVID-19 had a mild-moderate infection, with no more relapses or more severe disease course than MS-free patients. This session shed light on the response to vaccination of MS patients, including the influence of the chosen MS treatment on vaccine response. Watch to hear more about the production of antibodies in vaccinated MS patients and the influence of the MS treatment on antibodies production.


CELIA OREJA-GUEVARA
Vice Chair of Neurology and Head of Multiple Sclerosis Center at University Hospital San Carlos, Madrid

Professor Celia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos, Madrid and Professor of Neurology at the University Complutense, Madrid, Spain.
After receiving her MD from the University Complutense, Madrid, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology, University of Munich, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany),Hospital de Fuenlabrada and at the University Hospital La Paz, both in Madrid.

Professor Oreja-Guevara’s research interests centre on clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest, and Professor Oreja-Guevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO. As an investigator, she has participated in a number of MS clinical trials and currently heads the Neuroimaging Group of the Spanish Neurological Society, and she is a member of the Scientific Committee of the European Academy of Neurology. Currently, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency.


Media

Details

  • Directors

    ParadigMS
  • Author(s)

    Prof Celia Oreja-Guevara
  • Country

    Abu Dhabi
  • Release Date

    December 09, 2021
  • Views


FAQs

Do subscriptions auto-renew?
Your subscription will automatically renew on a monthly or yearly basis, depending on the plan you have chosen. If you cancel your plan, it will not renew at the end of your subscription cycle. It will end once the period you have paid for is over.
What happens if I subscribe as a healthcare practitioner if I am not a healthcare practitioner?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, you will be banned immediately from the community and could be liable to prosecution.
How can I cancel my trial or subscription?
You can cancel your trial or subscription in your account settings. If you cancel during the trial period you will not be charged.